Search

Search Constraints

You searched for: Author/Creator Langkilde, Anna Maria

Search Results

21. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Issue 11 (November 2021)

22. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Issue 11 (November 2021)

23. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. (27th August 2021)

24. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. (28th March 2020)

25. Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF. (18th January 2021)

26. Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria. Issue 11 (November 2022)

27. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Issue 8 (August 2019)

28. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Issue 4 (April 2023)

29. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Issue 1 (January 2021)

30. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. (1st April 2021)